Other Articles |


Thomas W. Baker, M.D.; Louis A. Brunsting, M.D.
JAMA. 1937;108(7):549-550. doi:10.1001/jama.1937.92780070002010a.
Text Size: A A A
Published online

Sulfocyanates have enjoyed varying degrees of popularity in the treatment of essential hypertension since their introduction by Westphal1 in 1924, following the observations of Pauli2 in 1903. However, much of the early enthusiasm for this drug has waned as its toxic manifestations have become evident. The high incidence of alarming cerebral symptoms in cases in which patients receive either potassium sulfocyanate or sodium sulfocyanate serves as a definite caution against the indiscriminate and prolonged use of either of these drugs.3 Although sulfocyanates have fallen into disrepute as a therapeutic agent of any permanent value in the treatment of essential hypertension, they continue to be used freely in proprietary preparations designed to lower the blood pressure.

The dermatoses that result from the use of sulfocyanates have not received the attention which they deserve. From the literature we have been able to collect only nine reports of cases in which


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.